• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

结核分枝杆菌耐药性的适合度代价

Fitness cost of drug resistance in Mycobacterium tuberculosis.

作者信息

Gagneux S

机构信息

Division of Mycobacterial Research, MRC National Institute for Medical Research, Mill Hill, London, UK.

出版信息

Clin Microbiol Infect. 2009 Jan;15 Suppl 1:66-8. doi: 10.1111/j.1469-0691.2008.02685.x.

DOI:10.1111/j.1469-0691.2008.02685.x
PMID:19220360
Abstract

Multidrug-resistant (MDR)--and extensively drug-resistant (XDR)--forms of tuberculosis are growing public health problems. Mathematical models predict that the future of the MDR and XDR tuberculosis epidemics depends in part on the competitive fitness of drug-resistant strains. Here, recent experimental and molecular epidemiological data that illustrate how heterogeneity among drug-resistant strains of Mycobacterium tuberculosis can influence the relative fitness and transmission of this pathogen are reviewed.

摘要

耐多药（MDR）和广泛耐药（XDR）形式的结核病正日益成为公共卫生问题。数学模型预测，耐多药和广泛耐药结核病流行的未来部分取决于耐药菌株的竞争适应性。在此，我们综述了近期的实验和分子流行病学数据，这些数据阐明了结核分枝杆菌耐药菌株之间的异质性如何影响该病原体的相对适应性和传播。

相似文献

1
Fitness cost of drug resistance in Mycobacterium tuberculosis.结核分枝杆菌耐药性的适合度代价
Clin Microbiol Infect. 2009 Jan;15 Suppl 1:66-8. doi: 10.1111/j.1469-0691.2008.02685.x.
2
Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis.耐药结核分枝杆菌的传染性、生殖适应性和进化。
Int J Tuberc Lung Dis. 2009 Dec;13(12):1456-66.
3
Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study.耐多药结核分枝杆菌耐药突变的适合度代价：一项基于家庭的病例对照研究
J Infect Dis. 2016 Jan 1;213(1):149-55. doi: 10.1093/infdis/jiv347. Epub 2015 Jun 19.
4
The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.耐多药结核分枝杆菌的异质性进化。
Trends Genet. 2013 Mar;29(3):160-9. doi: 10.1016/j.tig.2012.11.005. Epub 2012 Dec 13.
5
First insights into circulating XDR and pre-XDR Mycobacterium tuberculosis in Southern Brazil.巴西南部流行的广泛耐药和耐多药结核分枝杆菌的初步研究。
Infect Genet Evol. 2020 Mar;78:104127. doi: 10.1016/j.meegid.2019.104127. Epub 2019 Nov 26.
6
Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.W-北京型和非北京型结核分枝杆菌亚谱系感染的肺结核患者的社会人口学和临床特征比较
Tuberculosis (Edinb). 2016 Mar;97:18-25. doi: 10.1016/j.tube.2015.11.007. Epub 2015 Dec 23.
7
The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.结核分枝杆菌中抗生素耐药性的竞争代价。
Science. 2006 Jun 30;312(5782):1944-6. doi: 10.1126/science.1124410.
8
Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis.结核分枝杆菌的耐药性、适应性和补偿性突变。
Tuberculosis (Edinb). 2021 Jul;129:102091. doi: 10.1016/j.tube.2021.102091. Epub 2021 May 21.
9
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.高氟喹诺酮耐药比例在孟买大都市区由主导 L2 结核分枝杆菌克隆驱动的耐多药结核病中。
Genome Med. 2022 Aug 22;14(1):95. doi: 10.1186/s13073-022-01076-0.
10
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness.对具有异质性适应性的耐多药结核分枝杆菌流行病进行建模。
Nat Med. 2004 Oct;10(10):1117-21. doi: 10.1038/nm1110. Epub 2004 Sep 19.

引用本文的文献

1
Development and validation of a nomogram predicting multidrug-resistant tuberculosis risk in East China.华东地区预测耐多药结核病风险的列线图的开发与验证
PeerJ. 2025 Feb 27;13:e19112. doi: 10.7717/peerj.19112. eCollection 2025.
2
Rifampicin tolerance and growth fitness among isoniazid-resistant clinical isolates from a longitudinal study.利福平耐药性和纵向研究中耐异烟肼临床分离株的生长适应性。
Elife. 2024 Sep 9;13:RP93243. doi: 10.7554/eLife.93243.
3
Genetic diversity, evolution and drug resistance of lineage 2.2型谱系的遗传多样性、进化及耐药性
Front Microbiol. 2024 May 17;15:1384791. doi: 10.3389/fmicb.2024.1384791. eCollection 2024.
4
Multidrug-resistant tuberculosis.耐多药结核病。
Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
5
Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy.表型与基因型不一致的利福平药敏试验在结核病中的诊断价值：对诊断准确性的影响。
Microbiol Spectr. 2024 Jan 11;12(1):e0163123. doi: 10.1128/spectrum.01631-23. Epub 2023 Nov 20.
6
Genomic Characterization of Drug-Resistant L2/Beijing Isolates from Astana, Kazakhstan.来自哈萨克斯坦阿斯塔纳的耐多药L2/北京基因型菌株的基因组特征分析
Antibiotics (Basel). 2023 Oct 10;12(10):1523. doi: 10.3390/antibiotics12101523.
7
Borderline mutations transmit at the same rate as common mutations in a tuberculosis cohort in Bangladesh.孟加拉国结核队列中，交界突变的传播率与常见突变相同。
Microb Genom. 2023 Sep;9(9). doi: 10.1099/mgen.0.001109.
8
Evolution and epidemic success of Mycobacterium tuberculosis in eastern China: evidence from a prospective study.中国东部地区结核分枝杆菌的进化和流行成功：一项前瞻性研究的证据。
BMC Genomics. 2023 May 5;24(1):241. doi: 10.1186/s12864-023-09312-6.
9
Whole genome sequencing analysis to evaluate the influence of T2DM on polymorphisms associated with drug resistance in M. tuberculosis.全基因组测序分析评估 T2DM 对与结核分枝杆菌耐药性相关的多态性的影响。
BMC Genomics. 2022 Jun 24;23(1):465. doi: 10.1186/s12864-022-08709-z.
10
Estimating tuberculosis drug resistance amplification rates in high-burden settings.估算高负担地区的结核耐药扩增率。
BMC Infect Dis. 2022 Jan 24;22(1):82. doi: 10.1186/s12879-022-07067-1.